Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

By Hofer Silvia   Elandt Katarzyna   Greil Richard   Hottinger Andreas F.   Huber Urs   Lemke Dieter   Marosi Christine   Ochsenbein Adrian   Pichler Josef   Roelcke Ulrich   Weder Patrik   Zander Thilo   Wick Wolfgang   Weller Michael  

Acta Oncologica, Vol. 50, Iss. 5, 2011-06 ,pp. : 630-635

Informa Healthcare

Access to resources Recommend Favorite

Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option

By Flieger Maya   Ganswindt Ute   Schwarz Silke   Kreth Friedrich-Wilhelm   Tonn Jörg-Christian   Fougère Christian   Ertl Lorenz   Linn Jennifer   Herrlinger Ulrich   Belka Claus   Niyazi Maximilian  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 337-345

Springer Publishing Company

Access to resources Recommend Favorite

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

By Peters Katherine   Coyle Thomas   Vredenburgh James   Desjardins Annick   Friedman Henry   Reardon David  

Journal of Neuro-Oncology, Vol. 101, Iss. 1, 2011-01 ,pp. : 155-159

Springer Publishing Company

Access to resources Recommend Favorite

Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma

By Su Ying-Wen   Chang Ming-Chih   Chiang Ming-Fu   Hsieh Ruey-Kuen  

Journal of Neuro-Oncology, Vol. 71, Iss. 3, 2005-02 ,pp. : 315-318

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

By Neyns B.   Sadones J.   Chaskis C.   Dujardin M.   Everaert H.   Lv S.   Duerinck J.   Tynninen O.   Nupponen N.   Michotte A.   Greve J.  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 491-501

Springer Publishing Company

Access to resources Recommend Favorite